Photobiomodulation at 660 nm enhances proliferative activity while preserving viability in human endothelial cells in vitro

What the authors concluded

At 72 h, all irradiated groups showed significantly greater metabolic activity than the control group (1.0 J/cm2, p < 0.01; 4.0 and 7.5 J/cm2, p < 0.001), whereas viability remained high across all groups (> 95%), with no evidence of cytotoxicity. PBM redistributed cells toward proliferative phases, with a higher proportion of S-phase cells at 1.0 J/cm2 and greater accumulation in G2/M at 4.0 a

Devices that emit this wavelength

Matched on wavelength within 15nm, since LED bins vary by roughly that much and a tighter match would be false precision. Where we have an irradiance figure, the session length is the time needed to reach this study's dose of 1 J/cm² at that intensity.

Matching a wavelength is not the same as reproducing a trial. Session times assume the device's published irradiance is accurate at the distance it was measured, which on brand-claim figures is often optimistic. Where a device publishes both a peak and an average we use the average, and where it publishes a falloff curve we use the lowest figure, so these times run long rather than short. Clinical protocols also control for spot size, contact and skin type in ways a home device cannot.